Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 08 - 02 tags : Fda save search
Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, "Off-the-Shelf", Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma
Published: 2021-08-02 (Crawled : 14:00) - biospace.com/
SRNE | $0.028 42K
|
Health Technology
|
| O: 1.71%
H: 1.8%
C: -0.12%
fda phase 1 therapy trial authorized t-cell
FDA Clears Vaxart's IND Application for S-Only Oral Tablet COVID-19 Vaccine Candidate
Published: 2021-08-02 (Crawled : 13:00) - biospace.com/
VXRT | News | $0.8576 -0.98% 490K
|
Health Technology
|
| O: 4.19%
H: 3.05%
C: -2.56%
covid fda vaccine fda clearance application covid-19
Avidity Biosciences Receives IND Clearance from FDA to Proceed with the Phase 1/2 MARINA™ Trial of AOC 1001 in Adults with Myotonic Dystrophy (DM1)
Published: 2021-08-02 (Crawled : 13:00) - biospace.com/
RNA | $22.95 -2.55% 670K
|
Health Technology
|
| O: 0.76%
H: 5.74%
C: 4.3%
fda phase 1 trial clearance
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa for the Treatment of Mucosal Melanoma
Published: 2021-08-02 (Crawled : 12:00) - biospace.com/
ALKS | News | $23.75 -1.08% 800K
|
Health Technology
|
| O: 2.62%
H: 3.09%
C: 2.82%
treatment fda fda fast track fast track nemvaleukin mucosal melanoma fast track designation designation
FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study
Published: 2021-08-02 (Crawled : 12:00) - prnewswire.com
GLMD | $0.3669 -0.41% 21K
|
Health Technology
|
| O: 7.6%
H: 27.14%
C: 8.55%
fda phase 3 aramchol
Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca's anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)
Published: 2021-08-02 (Crawled : 12:00) - biospace.com/
AZN | $68.38 -0.22% 2.3M
|
Health Technology
|
| O: -0.7%
H: 0.86%
C: 0.58%
fda fda approval research approval lupus
Protalix BioTherapeutics Announces Submission of Type A Meeting Request to the FDA
Published: 2021-08-02 (Crawled : 11:00) - prnewswire.com
PLX | $1.135 -1.3% 130K
|
Health Services
|
| O: 0.65%
H: 2.6%
C: 2.6%
fda iot submission
Gainers vs Losers
| 69% | 31% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
ISPC | $0.4621 116.95% 15M
|
Professional, Scientific, and T...
INVO | $1.515 99.34% 4.3M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
XPON | $2.63 36.27% 8.4M
|
PRTG | $0.299 35.17% 120K
|
Mining, Quarrying, and Oil and ...
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
SWVL | $9.64 27.35% 200K
|
n/a
DFLI A | $0.7726 25.52% 4.3M
|
Your saved searches
Save your searches and get alerts when important news are released.